The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2026α-Synuclein Pathology Beyond Lewy-related Pathology: α-synuclein Oligomers and Seeding Activity in LRRK2-related Parkinson’s Disease
Study Rationale:
Parkinson's disease is caused by the buildup of a protein called α-synuclein in brain cells, and, in most patients, this protein forms large clumps called Lewy...
-
Fall 2025 RFP: Data Advice To Action, 2026Identifying Blood-Based Proteomic Biomarkers of Cognitive Decline and its Pathological Heterogeneity in PD and DLB
Study Rationale:
Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB) both feature debilitating cognitive decline without reliably effective therapies. This dearth of...
-
Parkinson’s Disease Therapeutics Pipeline Program - Pre-Clinical, 2026Preclinical Efficacy Studies for CU-13001, a 15-Lipoxygenase Inhibitor for the Treatment of Parkinson’s Disease
Study Rationale:
For over 30 years, scientists have linked lipid oxidation, a type of damage to cellular fats, with Parkinson’s disease. However, the precise cause of this damage...
-
Research Grant, 2025Development of a Tau Oligomerization Inhibitor for the Treatment of Parkinson’s Disease
Study Rationale: Tau aggregation is caused by hyperphosphorylation and misfolding of the Tau protein in the brain, leading to cellular dysfunction and neurodegeneration. Preclinical and clinical...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Developing VDAC1 Oligomerization Inhibitor for Treating Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) damages brain cells that control movement, largely due to problems in the cells’ energy factories, called mitochondria. A protein called VDAC1 helps regulate...
-
Fall 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program-Biomarkers, 2025Use of CapScan as a Non-invasive Tool for Intestinal Fluid Alpha-synuclein and Gut Biomarker Detection in Patients with Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is linked to abnormal clumps of a protein in the body called alpha-synuclein (asyn), which can now be detected in living people using an advanced laboratory...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.